Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C.

Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.

PMID:
30042063
2.

Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.

Malgras B, Gayat E, Aoun O, Lo Dico R, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M; RENAPE Network.

Ann Surg Oncol. 2018 Jul 5. doi: 10.1245/s10434-018-6631-2. [Epub ahead of print]

PMID:
29978366
3.

[Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil].

Vaflard P, Ederhy S, Torregrosa C, André T, Cohen R, Lopez-Trabada D.

Bull Cancer. 2018 Jul - Aug;105(7-8):707-719. doi: 10.1016/j.bulcan.2018.05.005. Epub 2018 Jun 28. Review. French.

PMID:
29960638
4.

Eight weeks of resistance training in conjunction with glutathione and L-Citrulline supplementation increases lean mass and has no adverse effects on blood clinical safety markers in resistance-trained males.

Hwang P, Morales Marroquín FE, Gann J, Andre T, McKinley-Barnard S, Kim C, Morita M, Willoughby DS.

J Int Soc Sports Nutr. 2018 Jun 27;15(1):30. doi: 10.1186/s12970-018-0235-x.

5.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
6.

Prognostic value and characteristics of N1c colorectal cancer.

Bouquot M, Creavin B, Goasguen N, Chafai N, Tiret E, André T, Flejou JF, Parc Y, Lefevre JH, Svrcek M.

Colorectal Dis. 2018 Jun 12. doi: 10.1111/codi.14289. [Epub ahead of print]

PMID:
29894583
7.

Restrictive Breathing Mask Reduces Repetitions to Failure During a Session of Lower-Body Resistance Exercise.

Andre TL, Gann JJ, Hwang PS, Ziperman E, Magnussen MJ, Willoughby DS.

J Strength Cond Res. 2018 Aug;32(8):2103-2108. doi: 10.1519/JSC.0000000000002648.

PMID:
29847532
8.

[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]

André T, Taieb J; Pour l’intergroupe PRODIGE (GERCOR, Fédération française de cancérologie digestive, et Unicancer) et pour la Fondation ARCAD (Aide et recherche encancérologie digestive).

Bull Cancer. 2018 Jun;105(6):546-547. doi: 10.1016/j.bulcan.2018.04.002. French. No abstract available.

PMID:
29776587
9.

Rectal and anal canal neuroendocrine tumours.

André TR, Brito M, Freire JG, Moreira A.

J Gastrointest Oncol. 2018 Apr;9(2):354-357. doi: 10.21037/jgo.2017.10.01.

10.

Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.

Auclin E, André T, Taieb J, Benetkiewicz M, de Gramont A, Vernerey D.

Eur J Cancer. 2018 Jul;97:55-56. doi: 10.1016/j.ejca.2018.03.032. Epub 2018 May 3. No abstract available.

PMID:
29731226
11.

Publisher Correction: Control of laser plasma accelerated electrons for light sources.

André T, Andriyash IA, Loulergue A, Labat M, Roussel E, Ghaith A, Khojoyan M, Thaury C, Valléau M, Briquez F, Marteau F, Tavakoli K, N'Gotta P, Dietrich Y, Lambert G, Malka V, Benabderrahmane C, Vétéran J, Chapuis L, El Ajjouri T, Sebdaoui M, Hubert N, Marcouillé O, Berteaud P, Leclercq N, El Ajjouri M, Rommeluère P, Bouvet F, Duval J-, Kitegi C, Blache F, Mahieu B, Corde S, Gautier J, Ta Phuoc K, Goddet JP, Lestrade A, Herbeaux C, Évain C, Szwaj C, Bielawski S, Tafzi A, Rousseau P, Smartsev S, Polack F, Dennetière D, Bourassin-Bouchet C, De Oliveira C, Couprie M-.

Nat Commun. 2018 May 2;9(1):1814. doi: 10.1038/s41467-018-04299-1.

12.

Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.

Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T, Peeters M.

Clin Colorectal Cancer. 2018 Mar 8. pii: S1533-0028(17)30493-0. doi: 10.1016/j.clcc.2018.03.005. [Epub ahead of print]

13.

Control of laser plasma accelerated electrons for light sources.

André T, Andriyash IA, Loulergue A, Labat M, Roussel E, Ghaith A, Khojoyan M, Thaury C, Valléau M, Briquez F, Marteau F, Tavakoli K, N'Gotta P, Dietrich Y, Lambert G, Malka V, Benabderrahmane C, Vétéran J, Chapuis L, El Ajjouri T, Sebdaoui M, Hubert N, Marcouillé O, Berteaud P, Leclercq N, El Ajjouri M, Rommeluère P, Bouvet F, Duval J-, Kitegi C, Blache F, Mahieu B, Corde S, Gautier J, Ta Phuoc K, Goddet JP, Lestrade A, Herbeaux C, Évain C, Szwaj C, Bielawski S, Tafzi A, Rousseau P, Smartsev S, Polack F, Dennetière D, Bourassin-Bouchet C, De Oliveira C, Couprie ME.

Nat Commun. 2018 Apr 6;9(1):1334. doi: 10.1038/s41467-018-03776-x. Erratum in: Nat Commun. 2018 May 2;9(1):1814.

14.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER.

J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.

PMID:
29620995
15.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T.

N Engl J Med. 2018 Mar 29;378(13):1177-1188. doi: 10.1056/NEJMoa1713709.

PMID:
29590544
16.
17.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.

Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E.

Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8.

PMID:
29518779
18.

Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status.

Mésange P, Bouygues A, Ferrand N, Sabbah M, Escargueil AE, Savina A, Chibaudel B, Tournigand C, André T, de Gramont A, Larsen AK.

Clin Cancer Res. 2018 Jun 1;24(11):2548-2558. doi: 10.1158/1078-0432.CCR-17-3187. Epub 2018 Feb 28.

PMID:
29490990
19.

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, André T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A.

Ann Oncol. 2018 May 1;29(5):1099-1107. doi: 10.1093/annonc/mdy064.

PMID:
29438451
20.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E.

Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5.

PMID:
29431699
21.

Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK).

Michel P, Boige V, Andre T, Aparicio T, Bachet JB, Dahan L, Guimbaud R, Lepage C, Manfredi S, Tougeron D, Taieb J, Selves J, Le Malicot K, Di Fiore F, Maillard E.

Dig Liver Dis. 2018 Mar;50(3):305-307. doi: 10.1016/j.dld.2017.12.023. Epub 2017 Dec 30.

PMID:
29402752
22.

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.

Sobhani I, Itti E, Luciani A, Baumgaertner I, Layese R, André T, Ducreux M, Gornet JM, Goujon G, Aparicio T, Taieb J, Bachet JB, Hemery F, Retbi A, Mons M, Flicoteaux R, Rhein B, Baron S, Cherrak I, Rufat P, Le Corvoisier P, de'Angelis N, Natella PA, Maoulida H, Tournigand C, Durand Zaleski I, Bastuji-Garin S.

Ann Oncol. 2018 Apr 1;29(4):931-937. doi: 10.1093/annonc/mdy031.

23.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

PMID:
29355075
24.

Electron and photon diagnostics for plasma acceleration-based FELs.

Labat M, El Ajjouri M, Hubert N, Andre T, Loulergue A, Couprie ME.

J Synchrotron Radiat. 2018 Jan 1;25(Pt 1):59-67. doi: 10.1107/S1600577517011742. Epub 2018 Jan 1.

PMID:
29271752
25.

[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO.

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006. Review. French.

PMID:
29269176
26.

Effects of 2% Dehydration on Lactate Concentration During Constant-Load Cycling.

Green JM, Miller B, Simpson J, Dubroc D, Keyes A, Neal K, Gann J, Andre T.

J Strength Cond Res. 2018 Jul;32(7):2066-2071. doi: 10.1519/JSC.0000000000002293.

PMID:
29239983
27.

Systemic Treatment of Metastatic Conjunctival Melanoma.

Pinto Torres S, André T, Gouveia E, Costa L, Passos MJ.

Case Rep Oncol Med. 2017;2017:4623964. doi: 10.1155/2017/4623964. Epub 2017 Oct 26.

28.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Lupinacci RM, Goloudina A, Buhard O, Bachet JB, Maréchal R, Demetter P, Cros J, Bardier-Dupas A, Collura A, Cervera P, Scriva A, Dumont S, Hammel P, Sauvanet A, Louvet C, Delpéro JR, Paye F, Vaillant JC, André T, Closset J, Emile JF, Van Laethem JL, Jonchère V, Abd Alsamad I, Antoine M, Rodenas A, Fléjou JF, Dusetti N, Iovanna J, Duval A, Svrcek M.

Gastroenterology. 2018 Mar;154(4):1061-1065. doi: 10.1053/j.gastro.2017.11.009. Epub 2017 Nov 20.

PMID:
29158190
29.

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

Cohen R, Buhard O, Cervera P, Hain E, Dumont S, Bardier A, Bachet JB, Gornet JM, Lopez-Trabada D, Dumont S, Kaci R, Bertheau P, Renaud F, Bibeau F, Parc Y, Vernerey D, Duval A, Svrcek M, André T.

Eur J Cancer. 2017 Nov;86:266-274. doi: 10.1016/j.ejca.2017.09.022. Epub 2017 Oct 19.

PMID:
29055842
30.

Effectiveness of Fish Oil Supplementation in Attenuating Exercise-Induced Muscle Damage in Women During Midfollicular and Midluteal Menstrual Phases.

McKinley-Barnard SK, Andre TL, Gann JJ, Hwang PS, Willoughby DS.

J Strength Cond Res. 2018 Jun;32(6):1601-1612. doi: 10.1519/JSC.0000000000002247.

PMID:
28930874
31.

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx136.

PMID:
28922790
32.

Reply to the Letter by S. Sorscher Regarding "Implications of BRAF Mutations in dMMR Colorectal Cancers".

Cohen R, André T.

Curr Treat Options Oncol. 2017 Sep 18;18(10):63. doi: 10.1007/s11864-017-0505-x.

PMID:
28921484
33.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.

BMC Cancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0.

34.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.

PMID:
28734759
35.

Molecular analysis of sentinel lymph node in colon carcinomas by one-step nucleic acid amplification (OSNA) reduces time to adjuvant chemotherapy interval.

Marhic A, Tremblay JF, Kaci R, André T, Eveno C, Pocard M.

Dig Liver Dis. 2017 Aug;49(8):924-928. doi: 10.1016/j.dld.2017.05.017. Epub 2017 May 30.

PMID:
28668271
36.

BIOLOGICAL AND PHYTOCHEMICAL INVESTIGATIONS OF EXTRACTS FROM PTEROCARPUS ERINACEUS POIR (FABACEAE) ROOT BARKS.

Noufou O, Anne-Emmanuelle H, Claude W OJ, Richard SW, André T, Marius L, Jean-Baptiste N, Jean K, Marie-Genevieve DF, Pierre GI.

Afr J Tradit Complement Altern Med. 2016 Nov 23;14(1):187-195. doi: 10.21010/ajtcam.v14i1.21. eCollection 2017.

37.

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.

Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T, Peeters M.

Ann Oncol. 2017 Aug 1;28(8):1862-1868. doi: 10.1093/annonc/mdx119.

38.

Genetic control of plasticity of oil yield for combined abiotic stresses using a joint approach of crop modelling and genome-wide association.

Mangin B, Casadebaig P, Cadic E, Blanchet N, Boniface MC, Carrère S, Gouzy J, Legrand L, Mayjonade B, Pouilly N, André T, Coque M, Piquemal J, Laporte M, Vincourt P, Muños S, Langlade NB.

Plant Cell Environ. 2017 Oct;40(10):2276-2291. doi: 10.1111/pce.12961. Epub 2017 Aug 24.

PMID:
28418069
39.

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.

Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28.

PMID:
28397697
40.

Systematic identification of phosphorylation-mediated protein interaction switches.

Betts MJ, Wichmann O, Utz M, Andre T, Petsalaki E, Minguez P, Parca L, Roth FP, Gavin AC, Bork P, Russell RB.

PLoS Comput Biol. 2017 Mar 27;13(3):e1005462. doi: 10.1371/journal.pcbi.1005462. eCollection 2017 Mar.

41.

Resistance Training-Induced Elevations in Muscular Strength in Trained Men Are Maintained After 2 Weeks of Detraining and Not Differentially Affected by Whey Protein Supplementation.

Hwang PS, Andre TL, McKinley-Barnard SK, Morales Marroquín FE, Gann JJ, Song JJ, Willoughby DS.

J Strength Cond Res. 2017 Apr;31(4):869-881. doi: 10.1519/JSC.0000000000001807.

PMID:
28328712
42.

BAIBA Does Not Regulate UCP-3 Expression in Human Skeletal Muscle as a Response to Aerobic Exercise.

Morales FE, Forsse JS, Andre TL, McKinley-Barnard SK, Hwang PS, Anthony IG, Tinsley GM, Spillane M, Grandjean PW, Ramirez A, Willoughby DS.

J Am Coll Nutr. 2017 Mar-Apr;36(3):200-209. doi: 10.1080/07315724.2016.1256240. Epub 2017 Mar 20.

PMID:
28318397
43.

Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).

Bennouna J, Phelip JM, André T, Asselain B, Sébastien Koné, Ducreux M.

Clin Colorectal Cancer. 2017 Jun;16(2):129-140.e4. doi: 10.1016/j.clcc.2016.07.013. Epub 2016 Aug 9.

PMID:
28277294
44.

BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?

Cohen R, Cervera P, Svrcek M, Pellat A, Dreyer C, de Gramont A, André T.

Curr Treat Options Oncol. 2017 Feb;18(2):9. doi: 10.1007/s11864-017-0453-5. Review.

PMID:
28214977
45.

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Gérard JP, André T, Bibeau F, Conroy T, Legoux JL, Portier G, Bosset JF, Cadiot G, Bouché O, Bedenne L; Société Française de Chirurgie Digestive (SFCD), Société Française d’Endoscopie Digestive (SFED0), Société Française de Radiothérapie Oncologique (SFRO).

Dig Liver Dis. 2017 Apr;49(4):359-367. doi: 10.1016/j.dld.2017.01.152. Epub 2017 Jan 20.

PMID:
28179091
46.

Cybersecurity: an enterprise risk issue.

Andre T.

Healthc Financ Manage. 2017 Feb;71(2):40-5. No abstract available.

PMID:
29901971
47.

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.

Pilati C, Shinde J, Alexandrov LB, Assié G, André T, Hélias-Rodzewicz Z, Ducoudray R, Le Corre D, Zucman-Rossi J, Emile JF, Bertherat J, Letouzé E, Laurent-Puig P.

J Pathol. 2017 May;242(1):10-15. doi: 10.1002/path.4880. Epub 2017 Mar 29.

PMID:
28127763
48.

[Immune response and digestive cancers: Prognostic and therapeutic implications].

Bibeau F, Bazille C, Svrcek M, Pierson R, Lagorce-Pagès C, Cohen R, André T.

Ann Pathol. 2017 Feb;37(1):111-116. doi: 10.1016/j.annpat.2016.12.008. Epub 2017 Jan 19. Review. French.

PMID:
28111038
49.

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.

Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J, Nemecek R, Rogowski W, Lesniewski-Kmak K, Petruzelka L, Apte RN, Mohanty P, Stecher M, Simard J, de Gramont A.

Lancet Oncol. 2017 Feb;18(2):192-201. doi: 10.1016/S1470-2045(17)30006-2. Epub 2017 Jan 14.

PMID:
28094194
50.

[Which recent results in Oncology and Hematology will have an impact on our practices? The point of vue of Bulletin du Cancer editorial board].

Vignot S, André T, Gonçalves A, Guièze R, Magné N, Orbach D, Penel N, Thariat J, Wislez M, Bay JO.

Bull Cancer. 2017 Jan;104(1):6-19. doi: 10.1016/j.bulcan.2016.11.009. Epub 2016 Dec 19. Review. French.

PMID:
28007296

Supplemental Content

Support Center